Quick Answer
Actinium Pharmaceuticals, Inc. reported Net Income Loss of -$33.89 million for the year ending 2025.
- Actinium Pharmaceuticals, Inc. showed an increase of +11.4% in Net Income Loss from 2024 to 2025.
- This data is from Actinium Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2003 to 2025 (23 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 23 years of available data (2003 to 2025), Actinium Pharmaceuticals, Inc.'s Net Income Loss has declined by 859.4%.
- Historical annual values: Fiscal year 2025: -$33.89 million | Fiscal year 2024: -$38.24 million | Fiscal year 2023: -$48.82 million | Fiscal year 2022: -$33.02 million | Fiscal year 2021: -$24.77 million | Fiscal year 2020: -$22.22 million | Fiscal year 2019: -$21.90 million | Fiscal year 2018: -$23.65 million | Fiscal year 2017: -$26.60 million | Fiscal year 2016: -$24.32 million | Fiscal year 2015: -$21.03 million | Fiscal year 2014: -$24.69 million | Fiscal year 2013: -$10.77 million | Fiscal year 2012: -$8.36 million | Fiscal year 2011: -$3.44 million | Fiscal year 2010: -$467.3 thousand | Fiscal year 2009: -$3.43 million | Fiscal year 2008: -$5.57 million | Fiscal year 2007: -$5.62 million | Fiscal year 2006: -$6.05 million | Fiscal year 2005: -$4.58 million | Fiscal year 2004: -$5.73 million | Fiscal year 2003: -$3.53 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: